RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Rapid test to assess the escape of SARS-CoV-2 variants of concern
Heggestad, J. T., Britton, R. J., Kinnamon, D. S., Wall, S. A., Joh, D. Y., Hucknall, A. M., Olson, L. B., Anderson, J. G., Mazur, A., Wolfe, C. R., Oguin, T. H., Sullenger, B. A., Burke, T. W., Kraft, B. D., Sempowski, G. D., Woods, C. W., & Chilkoti, A. (2021). Rapid test to assess the escape of SARS-CoV-2 variants of concern. Science advances, 7(49), Article eabl7682. https://doi.org/10.1126/sciadv.abl7682
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1. Using CoVariant-SCAN, we assessed neutralization/blocking of monoclonal antibodies and plasma from COVID-19–positive and vaccinated individuals. For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized. We also showed that we can rapidly adapt the platform to detect nAbs against an additional variant—B.1.617.2 (Delta)—without reengineering or reoptimizing the assay. Results using CoVariant-SCAN are consistent with live virus neutralization assays and demonstrate that this easy-to-deploy test could be used to rapidly assess nAb response against multiple SARS-CoV-2 variants.
